0.50
-0.03(-5.66%)
Currency In USD
| Previous Close | 0.53 |
| Open | 0.52 |
| Day High | 0.52 |
| Day Low | 0.5 |
| 52-Week High | 4.5 |
| 52-Week Low | 0.46 |
| Volume | 689,398 |
| Average Volume | 21.33M |
| Market Cap | 7.7M |
| PE | 0.67 |
| EPS | 0.75 |
| Moving Average 50 Days | 0.58 |
| Moving Average 200 Days | 1 |
| Change | -0.03 |
If you invested $1000 in Scienture Holdings, Inc. (SCNX) since IPO date, it would be worth $70.76 as of January 20, 2026 at a share price of $0.53. Whereas If you bought $1000 worth of Scienture Holdings, Inc. (SCNX) shares 1 year ago, it would be worth $70.76 as of January 20, 2026 at a share price of $0.53.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment
GlobeNewswire Inc.
Jan 14, 2026 1:05 PM GMT
U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA
GlobeNewswire Inc.
Dec 22, 2025 1:05 PM GMT
U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies
SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
GlobeNewswire Inc.
Dec 10, 2025 1:05 PM GMT
U.S. Losartan market totals $245M annually with 71M prescriptions COMMACK, NY, Dec. 10, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on prov